A363250 Stock Overview
A biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Genesystem Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,970.00 |
| 52 Week High | ₩12,800.00 |
| 52 Week Low | ₩5,390.00 |
| Beta | 0.57 |
| 11 Month Change | 3.32% |
| 3 Month Change | -12.85% |
| 1 Year Change | -9.12% |
| 33 Year Change | -16.57% |
| 5 Year Change | n/a |
| Change since IPO | -42.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| A363250 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.6% | -8.1% | 2.9% |
| 1Y | -9.1% | 18.1% | -2.8% |
Return vs Industry: A363250 underperformed the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A363250 underperformed the KR Market which returned -4% over the past year.
Price Volatility
| A363250 volatility | |
|---|---|
| A363250 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A363250's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A363250's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.genesystem.co.kr |
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits.
Genesystem Co., Ltd. Fundamentals Summary
| A363250 fundamental statistics | |
|---|---|
| Market cap | ₩69.85b |
| Earnings (TTM) | -₩11.27b |
| Revenue (TTM) | ₩1.57b |
44.6x
P/S Ratio-6.2x
P/E RatioIs A363250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A363250 income statement (TTM) | |
|---|---|
| Revenue | ₩1.57b |
| Cost of Revenue | ₩2.47b |
| Gross Profit | -₩904.72m |
| Other Expenses | ₩10.36b |
| Earnings | -₩11.27b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61k |
| Gross Margin | -57.76% |
| Net Profit Margin | -719.17% |
| Debt/Equity Ratio | 13.7% |
How did A363250 perform over the long term?
See historical performance and comparison